Your browser doesn't support javascript.
loading
RAISING is a high-performance method for identifying random transgene integration sites.
Wada, Yusaku; Sato, Tomoo; Hasegawa, Hiroo; Matsudaira, Takahiro; Nao, Naganori; Coler-Reilly, Ariella L G; Tasaka, Tomohiko; Yamauchi, Shunsuke; Okagawa, Tomohiro; Momose, Haruka; Tanio, Michikazu; Kuramitsu, Madoka; Sasaki, Daisuke; Matsumoto, Nariyoshi; Yagishita, Naoko; Yamauchi, Junji; Araya, Natsumi; Tanabe, Kenichiro; Yamagishi, Makoto; Nakashima, Makoto; Nakahata, Shingo; Iha, Hidekatsu; Ogata, Masao; Muramatsu, Masamichi; Imaizumi, Yoshitaka; Uchimaru, Kaoru; Miyazaki, Yasushi; Konnai, Satoru; Yanagihara, Katsunori; Morishita, Kazuhiro; Watanabe, Toshiki; Yamano, Yoshihisa; Saito, Masumichi.
Afiliação
  • Wada Y; Biotechnological Research Support Division, FASMAC Co., Ltd, Atsugi, Kanagawa, 243-0021, Japan.
  • Sato T; Department of Rare Diseases Research, Institute of Medical Science, St. Marianna University School of Medicine, Kawasaki, Kanagawa, 216-8512, Japan.
  • Hasegawa H; Division of Neurology, Department of Internal Medicine, St. Marianna University School of Medicine, Kawasaki, Kanagawa, 216-8511, Japan.
  • Matsudaira T; Department of Laboratory Medicine, Nagasaki University Hospital, Nagasaki, 852-8501, Japan.
  • Nao N; Department of Laboratory Medicine, Nagasaki University Graduate School of Biomedical Sciences, Nagasaki, 852-8501, Japan.
  • Coler-Reilly ALG; Biotechnological Research Support Division, FASMAC Co., Ltd, Atsugi, Kanagawa, 243-0021, Japan.
  • Tasaka T; Division of International Research Promotion, International Institute for Zoonosis Control, Hokkaido University, Sapporo, 001-0020, Japan.
  • Yamauchi S; One Health Research Center, Hokkaido University, Sapporo, 060-0818, Japan.
  • Okagawa T; Department of Rare Diseases Research, Institute of Medical Science, St. Marianna University School of Medicine, Kawasaki, Kanagawa, 216-8512, Japan.
  • Momose H; Department of Internal Medicine, Division of Bone and Mineral Diseases, Washington University School of Medicine, St. Louis, MO, 63110, USA.
  • Tanio M; Affinity Science Corporation, Tokyo, 141-0031, Japan.
  • Kuramitsu M; Department of Laboratory Medicine, Nagasaki University Hospital, Nagasaki, 852-8501, Japan.
  • Sasaki D; Department of Advanced Pharmaceutics, Faculty of Veterinary Medicine, Hokkaido University, Hokkaido, 060-0818, Japan.
  • Matsumoto N; Department of Safety Research on Blood and Biological Products, National Institute of Infectious Diseases, Tokyo, 208-0011, Japan.
  • Yagishita N; Department of Safety Research on Blood and Biological Products, National Institute of Infectious Diseases, Tokyo, 208-0011, Japan.
  • Yamauchi J; Department of Safety Research on Blood and Biological Products, National Institute of Infectious Diseases, Tokyo, 208-0011, Japan.
  • Araya N; Department of Laboratory Medicine, Nagasaki University Hospital, Nagasaki, 852-8501, Japan.
  • Tanabe K; Department of Laboratory Medicine, Nagasaki University Hospital, Nagasaki, 852-8501, Japan.
  • Yamagishi M; Department of Rare Diseases Research, Institute of Medical Science, St. Marianna University School of Medicine, Kawasaki, Kanagawa, 216-8512, Japan.
  • Nakashima M; Department of Rare Diseases Research, Institute of Medical Science, St. Marianna University School of Medicine, Kawasaki, Kanagawa, 216-8512, Japan.
  • Nakahata S; Department of Rare Diseases Research, Institute of Medical Science, St. Marianna University School of Medicine, Kawasaki, Kanagawa, 216-8512, Japan.
  • Iha H; Pathophysiology and Bioregulation, St. Marianna University Graduate School of Medicine, Kawasaki, Kanagawa, 216-8511, Japan.
  • Ogata M; Department of Computational Biology and Medical Sciences, Graduate School of Frontier Sciences, The University of Tokyo, Tokyo, 108-8639, Japan.
  • Muramatsu M; Department of Computational Biology and Medical Sciences, Graduate School of Frontier Sciences, The University of Tokyo, Tokyo, 108-8639, Japan.
  • Imaizumi Y; Division of Tumor and Cellular Biochemistry, Department of Medical Sciences, University of Miyazaki, Miyazaki, 889-1692, Japan.
  • Uchimaru K; Department of Microbiology, Faculty of Medicine, Oita University, Oita, 879-5593, Japan.
  • Miyazaki Y; Department of Hematology, Oita University Hospital, Oita, 879-5593, Japan.
  • Konnai S; Department of Virology II, National Institute of Infectious Diseases, Tokyo, 162-8640, Japan.
  • Yanagihara K; Department of Hematology, Nagasaki University Hospital, Nagasaki, 852-8501, Japan.
  • Morishita K; Department of Computational Biology and Medical Sciences, Graduate School of Frontier Sciences, The University of Tokyo, Tokyo, 108-8639, Japan.
  • Watanabe T; Department of Hematology, Nagasaki University Hospital, Nagasaki, 852-8501, Japan.
  • Yamano Y; Atomic Bomb Disease and Hibakusha Medicine Unit, Atomic Bomb Disease Institute, Nagasaki University, Nagasaki, 852-8102, Japan.
  • Saito M; Department of Advanced Pharmaceutics, Faculty of Veterinary Medicine, Hokkaido University, Hokkaido, 060-0818, Japan.
Commun Biol ; 5(1): 535, 2022 06 02.
Article em En | MEDLINE | ID: mdl-35654946
Both natural viral infections and therapeutic interventions using viral vectors pose significant risks of malignant transformation. Monitoring for clonal expansion of infected cells is important for detecting cancer. Here we developed a novel method of tracking clonality via the detection of transgene integration sites. RAISING (Rapid Amplification of Integration Sites without Interference by Genomic DNA contamination) is a sensitive, inexpensive alternative to established methods. Its compatibility with Sanger sequencing combined with our CLOVA (Clonality Value) software is critical for those without access to expensive high throughput sequencing. We analyzed samples from 688 individuals infected with the retrovirus HTLV-1, which causes adult T-cell leukemia/lymphoma (ATL) to model our method. We defined a clonality value identifying ATL patients with 100% sensitivity and 94.8% specificity, and our longitudinal analysis also demonstrates the usefulness of ATL risk assessment. Future studies will confirm the broad applicability of our technology, especially in the emerging gene therapy sector.
Assuntos

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Vírus Linfotrópico T Tipo 1 Humano / Leucemia-Linfoma de Células T do Adulto Tipo de estudo: Clinical_trials / Risk_factors_studies Limite: Adult / Humans Idioma: En Revista: Commun Biol Ano de publicação: 2022 Tipo de documento: Article País de afiliação: Japão

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Vírus Linfotrópico T Tipo 1 Humano / Leucemia-Linfoma de Células T do Adulto Tipo de estudo: Clinical_trials / Risk_factors_studies Limite: Adult / Humans Idioma: En Revista: Commun Biol Ano de publicação: 2022 Tipo de documento: Article País de afiliação: Japão